Sumitomo Chemical Makes Strategic Investment in Conagen

Sumitomo Corporation Acquires Saconix LLC

June 8, 2023

Industrial Services

Sumitomo Corporation, through Sumitomo Corporation of Americas, has completed the acquisition of Saconix LLC from Copperbeck Energy Partners, making Saconix a wholly owned subsidiary of the Sumitomo Corporation Group. The deal adds sulfuric acid storage tanks and transloading facilities in the U.S. West and Gulf Coast, expanding Sumitomo's North American logistics capacity and boosting its global sulfuric acid trading and storage footprint.

Summa Equity Acquires Majority Stake in Sengenics

October 14, 2020

Biotechnology

Summa Equity Fund II has acquired a majority stake in Sengenics, a functional proteomics company that commercialises the KREX technology for full‑length, correctly folded protein production and autoantibody detection. The investment will support Sengenics' product development, global expansion and accelerated commercial adoption across pharma, academic research and diagnostics.

Solar Biotech Acquires Noblegen

July 25, 2023

Biotechnology

Solar Biotech Inc., a Norton, Virginia-based synthetic biology and bioprocessing company, has acquired Noblegen, an advanced digital biology and precision fermentation company based in Peterborough, Ontario. Noblegen will operate as Solar Biotech Canada and serve as the group's food-grade-certified biomanufacturing and R&D hub, expanding Solar Biotech's upstream/downstream capabilities and on‑the‑ground capacity in Canada.

Summa Equity Acquires Majority Stake in G-CON Manufacturing

July 15, 2021

Manufacturing

Summa Equity Fund II acquired a majority stake in G-CON Manufacturing, a College Station, Texas-based manufacturer of prefabricated POD cleanroom solutions, in a transaction that closed on July 15, 2021. The deal marks an entry for Summa into the biopharmaceutical manufacturing space and follows an exit by WP Global Partners, with Summa planning to expand G-CON’s product, service offering and international presence.

Ginkgo Bioworks Acquires Zymergen

July 25, 2022

Biotechnology

Ginkgo Bioworks (NYSE: DNA) will acquire Zymergen in an all‑stock transaction valuing Zymergen at about $300 million; Zymergen stockholders will receive 0.9179 Ginkgo shares per Zymergen share and will own ~5.25% of the combined company. The acquisition is intended to integrate Zymergen's automation, software, and data‑science capabilities and biological assets into Ginkgo's horizontal cell‑programming platform to expand capacity, capabilities, and efficiency across multiple end markets.

Formosa Laboratories Acquires SynChem to Expand North American CDMO Footprint

June 3, 2024

Pharmaceuticals

Formosa Laboratories, Inc., a Taiwan-based API supplier and CDMO, has completed its acquisition of SynChem, Inc., a contract research laboratory in suburban Chicago. SynChem will operate as SynChem-Formosa with Dr. W. Paul Mar remaining as CEO as the combined operations expand Formosa's US CDMO capabilities for small-molecule APIs and ADC-related chemistries.